Short Peptide Nanoparticle Vaccine Eradicates Kidney Cancer in Multiple Mouse Models
A short neoepitope peptide (Nes2LR) converted into immunogenic nanoparticles prevented and eradicated renal cell carcinoma in mice at ultra-low doses, synergizing with immune checkpoint therapy.
Quick Facts
What This Study Found
Single neoepitope Nes2LR as short peptide nanoparticle vaccine prevented tumor growth and eradicated disease in subcutaneous, lung metastasis, and orthotopic renal carcinoma models at doses orders of magnitude lower than other adjuvants. Synergized with checkpoint blockade.
Key Numbers
20 candidates; 1 functional (Nes2LR); worked in 20/60-plex; orders of magnitude lower dose; eradicated tumors in 3 models; synergized with checkpoint blockade
How They Did This
Preclinical study. RENCA murine renal carcinoma. 20 MHC-I neoepitopes predicted by sequencing. Screened as immunogenic nanoparticles. Nes2LR tested in subcutaneous, experimental lung metastasis, and orthotopic tumor models. Combination with immune checkpoint blockade.
Why This Research Matters
Most neoepitope vaccines require complex long peptides or mRNA delivery. This shows that simple short peptides converted to nanoparticles can achieve powerful anti-tumor immunity at ultra-low doses — potentially making cancer vaccines simpler and cheaper.
The Bigger Picture
Converting short peptides into nanoparticles is a scalable, cost-effective vaccine platform. The success with multivalent (20-60 peptide) particles suggests real-world personalized cancer vaccines could include many neoepitopes simultaneously without losing potency.
What This Study Doesn't Tell Us
Mouse renal carcinoma model — human tumors are more heterogeneous. Only 1 of 20 predicted neoepitopes was functionally active. Human MHC diversity makes neoepitope prediction more challenging. No human clinical data.
Questions This Raises
- ?Can this nanoparticle platform identify functional human neoepitopes as efficiently?
- ?Would combination with anti-PD-1 plus neoepitope vaccine become a standard renal cancer approach?
- ?How quickly can personalized neoepitope nanoparticle vaccines be manufactured for individual patients?
Trust & Context
- Key Stat:
- Ultra-low dose eradication The neoepitope nanoparticle vaccine eradicated tumors at doses orders of magnitude lower than other vaccine adjuvants — a dramatic improvement in potency
- Evidence Grade:
- Moderate evidence: comprehensive preclinical study with 3 tumor models and combination therapy, but mouse model only with no human data.
- Study Age:
- Published 2021. Neoepitope cancer vaccines and peptide nanoparticle delivery are rapidly advancing toward human clinical trials.
- Original Title:
- Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model.
- Published In:
- Journal for immunotherapy of cancer, 9(12) (2021)
- Authors:
- He, Xuedan, Zhou, Shiqi, Dolan, Melissa, Shi, Yuhao, Wang, Jianxin, Quinn, Breandan, Jahagirdar, Dushyant, Huang, Wei-Chiao, Tsuji, Moriya, Pili, Roberto, Ito, Fumito, Ortega, Joaquin, Abrams, Scott I, Ebos, John M L, Lovell, Jonathan F
- Database ID:
- RPEP-05441
Evidence Hierarchy
Frequently Asked Questions
What is a neoepitope vaccine?
A neoepitope vaccine targets unique mutations found only in a patient's tumor. By teaching the immune system to recognize these mutations (via short peptide fragments), the vaccine triggers killer T cells that specifically attack cancer cells while sparing healthy tissue.
Why are nanoparticles important for this vaccine?
Converting short peptides into nanoparticles dramatically increases their ability to stimulate the immune system. In this study, the nanoparticle form worked at doses far lower than the same peptide with conventional vaccine adjuvants — making the vaccine both more potent and potentially more practical.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05441APA
He, Xuedan; Zhou, Shiqi; Dolan, Melissa; Shi, Yuhao; Wang, Jianxin; Quinn, Breandan; Jahagirdar, Dushyant; Huang, Wei-Chiao; Tsuji, Moriya; Pili, Roberto; Ito, Fumito; Ortega, Joaquin; Abrams, Scott I; Ebos, John M L; Lovell, Jonathan F. (2021). Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model.. Journal for immunotherapy of cancer, 9(12). https://doi.org/10.1136/jitc-2021-003101
MLA
He, Xuedan, et al. "Immunization with short peptide particles reveals a functional CD8+ T-cell neoepitope in a murine renal carcinoma model.." Journal for immunotherapy of cancer, 2021. https://doi.org/10.1136/jitc-2021-003101
RethinkPeptides
RethinkPeptides Research Database. "Immunization with short peptide particles reveals a function..." RPEP-05441. Retrieved from https://rethinkpeptides.com/research/he-2021-immunization-with-short-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.